Inventors:
Zilin Huang - San Leandro CA, US
Jeff Jin - San Ramon CA, US
Timothy Machajewski - Martinez CA, US
Maureen McKenna - Pinole CA, US
Daniel Poon - Piedmont CA, US
Paul A. Renhowe - Emeryville CA, US
Martin Sendzik - San Mateo CA, US
Cynthia Shafer - Moraga CA, US
Aaron Smith - Union City CA, US
Yongjin Xu - Castro Valley CA, US
Qiong Zhang - Union City CA, US
Zheng Chen - Fremont CA, US
International Classification:
A61K 31/444
A61K 31/506
C07D 403/14
C07D 405/14
A61K 31/4439
C07D 417/14
C07D 471/04
C07D 413/14
A61K 31/496
C07D 487/04
A61K 31/4985
C07D 498/04
A61K 31/5383
A61K 31/4709
A61K 31/5377
A61P 35/00
C07D 401/14
US Classification:
5142305, 546256, 514333, 544331, 514275, 544295, 51425505, 5462741, 514341, 5462697, 546113, 514300, 5462714, 544364, 51425218, 5462757, 514338, 5462721, 546122, 546119, 544350, 514249, 514303, 546121, 544105, 546167, 514314, 544122, 5142358, 514342, 514340
Abstract:
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.